Opioid Use Disorder
📧 Sign up to get email alerts when something new happens for Opioid Use Disorder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2025-12-22FDA Approved: DISKETS — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approves a supplemental application for DISKETS (methadone hydrochloride) by Hikma Pharmaceuticals USA Inc. The approval expands the lab…
-
FDA approval · 2025-12-22FDA Approved: VIVITROL — Supplemental Application (Alkermes, Inc.)
The FDA approved a supplemental application for VIVITROL (naltrexone) by Alkermes, Inc.
-
FDA approval · 2025-12-22FDA Approved: METHADONE HYDROCHLORIDE — Supplemental Application (Camber Pharmaceuticals, Inc)
FDA approved a supplemental application for Methadone Hydrochloride from Camber Pharmaceuticals, Inc, updating the product’s regulatory stat…
-
FDA approval · 2025-12-22FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (PAI Holdings, LLC dba Pharmaceutical Associates, Inc. and dba PAI Pharma)
FDA approved a supplemental application for a buprenorphine and naloxone product from PAI Holdings/PAI Pharma. The combination is used for t…
-
FDA approval · 2025-12-22FDA Approved: BUPRENORPHINE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for buprenorphine from Sun Pharmaceutical Industries, Inc.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2025-12-22FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Actavis Pharma, Inc.)
FDA approved a supplemental application for buprenorphine and naloxone from Actavis Pharma, Inc., expanding the availability of this generic…
-
FDA approval · 2025-12-22FDA Approved: METHADONE HYDROCHLORIDE — Supplemental Application (Epic Pharma, LLC)
FDA approved a supplemental application for methadone hydrochloride (Epic Pharma, LLC), approving a generic product under the ANDA pathway.
-
FDA approval · 2025-12-22FDA Approved: METHADONE HYDROCHLORIDE — Supplemental Application (SpecGx LLC)
FDA approved a supplemental application for METHADONE HYDROCHLORIDE from SpecGx LLC, confirming the generic product under ANDA 207537. This …
-
FDA approval · 2025-12-22FDA Approved: METHADONE HYDROCHLORIDE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for methadone hydrochloride from Hikma Pharmaceuticals USA Inc., resulting in a generic product appr…
-
CLINICAL_TRIALS trial_result · 2025-12-22Clinical Trial Update: Patient-Centered Opioid Tapering Study
Stanford-sponsored clinical trial investigating patient-centered tapering of opioid therapy for chronic pain and opioid use disorder has com…
-
CLINICAL_TRIALS research · 2025-12-22Clinical Trial Update: Pain and Opioids: Integrated Treatment In Veterans [NA]
Clinical trial update on integrated treatment for veterans addressing chronic pain and opioid use disorder; the study is currently active bu…
-
FDA approval · 2025-12-22FDA Approved: METHADONE HYDROCHLORIDE — Supplemental Application (Elite Laboratories, Inc.)
FDA approved a supplemental application for methadone hydrochloride (generic) from Elite Laboratories, Inc.
-
CLINICAL_TRIALS trial_result · 2025-12-18Clinical Trial Update: Mobile & Online-Based Interventions to Lessen Pain [Phase 3]
Phase 3 trial evaluating mobile and online-based interventions to lessen pain in chronic pain patients, including those with opioid use diso…
-
CLINICAL_TRIALS trial_result · 2025-12-18Clinical Trial Update: Trauma-informed, Resilience-based Telehealth Intervention for Improving HIV Prevention and HCV Care for Persons Who Inject Drugs in the Deep South (Pilot Testing: Aim3) [NA]
A clinical trial update describes a trauma-informed, resilience-based telehealth intervention designed to improve HIV prevention (PrEP) upta…
-
CLINICAL_TRIALS research · 2025-12-18Clinical Trial Update: Opioid Use Disorder in Pregnancy in Long-Term Maternal/Infant Outcomes
This clinical trial update indicates a recruiting study assessing long-term maternal and infant outcomes of opioid use disorder during pregn…
-
CLINICAL_TRIALS research · 2025-12-18Clinical Trial Update: MHealth Incentivized Adherence Plus Patient Navigation [NA]
This clinical trial entry provides an update on a mobile health program using incentivized adherence plus patient navigation for opioid use …
-
CLINICAL_TRIALS research · 2025-12-18Clinical Trial Update: Patient Decision Aid for Opioid Use Disorder [NA]
This clinical trial update describes a patient decision aid designed to help individuals with opioid use disorder make informed treatment ch…
-
CLINICAL_TRIALS trial_result · 2025-12-17Clinical Trial Update: Testing STAR and TexSTAR: A Video and Text Messaging Intervention [NA]
A completed clinical trial evaluating STAR and TexSTAR video and text messaging interventions for PTSD and opioid use disorder.
-
CLINICAL_TRIALS trial_result · 2025-12-16Clinical Trial Update: Proof of Concept and Dose-ranging Study of INDV-2000 in Individuals With Moderate to Severe Opioid Use Disorder [Phase 2]
INDV-2000, an investigational treatment from Indivior, completed a Phase 2 proof-of-concept and dose-ranging study in adults with moderate t…
-
CLINICAL_TRIALS research · 2025-12-16Clinical Trial Update: Psilocybin in Cancer Pain Study [Phase 2]
A Phase 2 clinical trial evaluating psilocybin for cancer-related pain is currently recruiting.
-
CLINICAL_TRIALS research · 2025-12-16Clinical Trial Update: Autonomous Methadone Delivery System by Nurses [NA]
A registered clinical trial evaluating an autonomous methadone delivery system administered by nurses for opioid use disorder, currently rec…
-
CLINICAL_TRIALS research · 2025-12-15Clinical Trial Update: Cannabis and Opioid Use Disorder [Phase 1]
A Phase 1 clinical trial sponsored by the University of Kentucky is investigating cannabis for opioid use disorder and is currently recruiti…
-
CLINICAL_TRIALS research · 2025-12-15Clinical Trial Update: Treating Polysubstance Use Using a Novel Digital Technology [Phase 3]
This entry reports that a Phase 3 trial evaluating a novel digital technology to treat polysubstance use, including opioid use disorder and …
-
CLINICAL_TRIALS research · 2025-12-15Clinical Trial Update: Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD) [Phase 2]
Phase 2 clinical trial update focused on optimizing retention, duration, and discontinuation strategies for pharmacotherapy in opioid use di…
-
FDA approval · 2025-12-15FDA Approved: BUPRENORPHINE AND NALOXONE — Original Application (Camber Pharmaceuticals, Inc.)
FDA approved Camber Pharmaceuticals' generic buprenorphine/naloxone product via an Original Application (ANDA).